{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:46:01Z","timestamp":1793781961256,"version":"4.6.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Switching from intravenous infliximab (IV-IFX) to subcutaneous biosimilar infliximab (SC-IFX) has been shown to safely maintain clinical remission and increase drug levels in patients with Crohn\u2019s disease (CD) and ulcerative colitis (UC). The aim of this study was to evaluate long-term outcomes after switching from IV-IFX to SC-IFX, including the drug concentration thresholds for maintaining remission and other predictors for loss of response after the switch.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter observational study involved CD and UC patients who were in clinical remission for at least 24 weeks and were scheduled to switch from IV-IFX to SC-IFX.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two hundred and twenty patients were included (74 UC [34%] and 146 CD [66%]). IV-IFX was administered for 52.5 months (range 25-89). Before switch, 106 (49%) patients were receiving intensified IV-IFX. While SC-IFX levels significantly increased following the switch from IV-IFX to SC-IFX, clinical parameters, C-reactive protein, and fecal calprotectin remained unchanged during follow-up. SC-IFX levels were significantly higher in patients receiving the standard IV-IFX dose than in those receiving the intensified dose. Immunomodulatory therapy at baseline and perianal disease had no effect on IFX trough levels, whereas higher body mass index was associated with increased levels. The suggested optimal SC-IFX cutoff concentration for clinical and biochemical remissions based on receiver operating characteristic analysis was 12.2 \u03bcg\/mL (area under the curve [AUC]: 0.62) at Week 12 and 13.2 \u03bcg\/mL (AUC: 0.57) at Week 52. Drug persistence was 92% at Week 52, with a good safety profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Switching from IV-IFX to SC-IFX safely maintains long-term remission in patients with CD and UC. In maintenance, the optimal cutoff point associated with remission was 12-13 \u03bcg\/mL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae127","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:40:01Z","timestamp":1724370001000},"source":"Crossref","is-referenced-by-count":20,"title":["Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA Registry"],"prefix":"10.1093","volume":"19","author":[{"given":"Marisa","family":"Iborra","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-6730","authenticated-orcid":false,"given":"Berta","family":"Caballol","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedad Inflamatoria Intestinal, Hospital Cl\u00ednic Barcelona, IDIBAPS, CIBERehd , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Garrido","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Huguet","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital General Universitario de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-8187","authenticated-orcid":false,"given":"Francisco","family":"Mesonero","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ponferrada","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Arias Garc\u00eda","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-8797","authenticated-orcid":false,"given":"Marta Maia","family":"Bosc\u00e1 Watts","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Cl\u00ednico Universitario de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J","family":"Fern\u00e1ndez Prada","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Rio Hortega , Valladolid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-0608","authenticated-orcid":false,"given":"Eduard","family":"Brunet Mas","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitari Parc Taul\u00ed, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT-CERCA , Sabadell ,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, CIBERehd , Sabadell , \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-4139","authenticated-orcid":false,"given":"Ana","family":"Guti\u00e9rrez Casbas","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital General Universitario Dr. Balmis de Alicante , ISABIAL, CIBERehd, Alicante ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Cerrillo","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Ord\u00e1s","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedad Inflamatoria Intestinal, Hospital Cl\u00ednic Barcelona, IDIBAPS, CIBERehd , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital General Universitario de Valencia , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garc\u00eda de la Filia","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Escobar Ortiz","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario Infanta Leonor , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Sicilia","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario de Burgos , Burgos ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ricart","sequence":"additional","affiliation":[{"name":"Unidad de Enfermedad Inflamatoria Intestinal, Hospital Cl\u00ednic Barcelona, IDIBAPS, CIBERehd , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitari Germans Trias i Pujol de Badalona , Barcelona ,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona, CIBERehd , Barcelona , \u00a0","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Nos","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Universitario y Polit\u00e9cnico La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2025012507061174600_CIT0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2020.1811849","article-title":"Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13","volume":"21","author":"Parigi","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2025012507061174600_CIT0002","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"2025012507061174600_CIT0003","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025012507061174600_CIT0004","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. Real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"key":"2025012507061174600_CIT0005","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025012507061174600_CIT0006","first-page":"118","article-title":"Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results","volume":"114","author":"Arg\u00fcelles-Arias","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"2025012507061174600_CIT0007","first-page":"jjae059","article-title":"Intravenous versus subcutaneous infliximab in","author":"Chetwood","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025012507061174600_CIT0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial","volume":"43","author":"D\u2019Haens","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2025012507061174600_CIT0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.16852","article-title":"Subcutaneous injection of infliximab","volume":"56","author":"Roblin","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2025012507061174600_CIT0010","doi-asserted-by":"crossref","first-page":"otad040","DOI":"10.1093\/crocol\/otad040","article-title":"Subcutaneous infliximab in refractory Crohn\u2019s disease patients: a possible biobetter","volume":"5","author":"Cerna","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2025012507061174600_CIT0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025012507061174600_CIT0012","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025012507061174600_CIT0013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.gastrohep.2020.05.007","article-title":"El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes gen\u00e9ticos y Ambientales) de GETECCU: dise\u00f1o, monitorizaci\u00f3n y funciones","volume":"43","author":"Zabana","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"2025012507061174600_CIT0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MOG.0000000000000536","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug","volume":"35","author":"Papamichael","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"2025012507061174600_CIT0015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are","volume":"18","author":"Roblin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025012507061174600_CIT0016","doi-asserted-by":"crossref","first-page":"1756284818759930","DOI":"10.1177\/1756284818759930","article-title":"Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn\u2019s disease","volume":"11","author":"Carlsen","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"2025012507061174600_CIT0017","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025012507061174600_CIT0018","doi-asserted-by":"crossref","first-page":"795272","DOI":"10.3389\/fphar.2021.795272","article-title":"Clinical and immunological factors associated with recommended trough levels of adalimumab and infliximab in patients with Crohn\u2019s disease","volume":"12","author":"Orts","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025012507061174600_CIT0019","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.3390\/jcm11206173","article-title":"Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease\u2014understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics","volume":"11","author":"Little","year":"2022","journal-title":"J Clin Med"},{"key":"2025012507061174600_CIT0020","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the","volume":"59","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2025012507061174600_CIT0021","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s12325-023-02457-6","article-title":"Dose escalation patterns of advanced therapies in Crohn\u2019s disease and ulcerative colitis: a systematic literature review","volume":"40","author":"Panaccione","year":"2023","journal-title":"Adv Ther"},{"key":"2025012507061174600_CIT0022","doi-asserted-by":"crossref","first-page":"17562848231201728","DOI":"10.1177\/17562848231201728","article-title":"10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification\u2014a nationwide population-based study","volume":"16","author":"Koo","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2025012507061174600_CIT0023","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cgh.2023.09.027","article-title":"Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post hoc analysis of the REMSWITCH study","volume":"22","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025012507061174600_CIT0024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MCG.0000000000001637","article-title":"Supratherapeutic infliximab levels do not predict risk of short-term complications in adults with Crohn\u2019s disease","volume":"57","author":"Bhattacharya","year":"2023","journal-title":"J Clin Gastroenterol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae127\/59028264\/jjae127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjae127\/59028264\/jjae127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/1\/jjae127\/59028264\/jjae127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T07:06:26Z","timestamp":1737788786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae127\/7738597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae127","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,22]]},"article-number":"jjae127"}}